QantX: Investment Portfolio & Startup News
QantX
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
Revolver Therapeutics develops peptide-based therapeutics designed to inhibit transcription factors, proteins inside cancer cells that drive tumour growth, survival and treatment resistance. Its Transcription Block Survival platform identifies cell-penetrating peptides that can switch off these targets, which have traditionally been considered too difficult to reach with conventional drugs.
Neuronostics raises £3m in funding led by Empirical Ventures and The FSE Group for platform that diagnoses epilepsy from brain activity recordings
Neuronostics develops BioEP, a digital biomarker platform that analyses EEG recordings to support the diagnosis and prognosis of epilepsy. The platform is designed for clinicians who need objective decision support when routine EEG results are inconclusive.
EnsiliTech raises £4.5m seed round led by Eos Advisory to transform global medicine storage and transport
EnsiliTech develops technology that stabilises vaccines and biologics at high temperatures, removing the need for cold-chain storage and improving global access to medicines.
- 2(12 months)
- qantx.co.uk
- Update Information
More venture news
- 26 Oct 2026
NousNous raises £13m in funding led by Heartcore Capital and Mosaic Ventures for an AI agent that manages household bills and admin
EquityConsumer - 19 Oct 2026
FrugaFruga secures a £1m in funding led by PXN Ventures to lower insurance renewal premiums through open banking
EquityFintech - 13 Oct 2026
SainapticSainaptic raises £1m in funding led by Cornerstone VC and Ufi Ventures for AI-assisted marking of vocational and professional qualifications
EquityEducation
